

Hirofumi Mukai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6841826/publications.pdf>

Version: 2024-02-01

62
papers

1,221
citations

394421

19
h-index

414414

32
g-index

63
all docs

63
docs citations

63
times ranked

1745
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2022, 29, 131-143.	2.9	1
2	One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry. <i>Thrombosis Research</i> , 2022, 213, 203-213.	1.7	12
3	Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. <i>Quality of Life Research</i> , 2022, 31, 1829-1836.	3.1	3
4	Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two-stage stochastic dynamic treatment regime approach. <i>Biometrics</i> , 2021, 77, 702-714.	1.4	3
5	The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. <i>Surgical Oncology</i> , 2021, 36, 51-55.	1.6	4
6	Analysis of subsequent therapy in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. <i>Breast Cancer</i> , 2021, 28, 335-345.	2.9	5
7	A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. <i>Clinical Breast Cancer</i> , 2021, 21, 450-457.	2.4	0
8	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.	2.9	10
9	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	1.6	16
10	Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1217-1225.	6.4	8
11	Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 74-84.	10.7	16
12	Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1246-1253.	1.3	43
13	Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. <i>Scientific Reports</i> , 2020, 10, 15530.	3.3	13
14	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	1.6	50
15	Factors affecting enrollment in randomized controlled trials conducted for patients with metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 873-881.	1.3	0
16	Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. <i>Investigational New Drugs</i> , 2020, 38, 1540-1549.	2.6	12
17	Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. <i>British Journal of Cancer</i> , 2020, 122, 1747-1753.	6.4	7
18	Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. <i>Breast Cancer</i> , 2019, 26, 637-650.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 631-635.	2.5	4
20	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019, 120, 475-480.	6.4	92
21	Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 262-273.	2.2	39
22	Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 274-287.	2.2	43
23	Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial). <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 388-391.	1.3	2
24	Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. <i>Pharmacoeconomics</i> , 2018, 36, 215-223.	3.3	21
25	Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer</i> , 2018, 25, 118-125.	2.9	9
26	Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer. <i>Oncology</i> , 2018, 94, 107-115.	1.9	8
27	Advances in chemotherapy for HER2-negative metastatic breast cancer. <i>Chinese Clinical Oncology</i> , 2018, 7, 26-26.	1.2	1
28	A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 307-314.	2.6	63
29	The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer. <i>Oncology</i> , 2017, 93, 315-322.	1.9	3
30	Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. <i>BMC Cancer</i> , 2017, 17, 773.	2.6	1
31	Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. <i>Oncotarget</i> , 2017, 8, 19039-19048.	1.8	21
32	Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. <i>Cancer Science</i> , 2016, 107, 755-763.	3.9	66
33	Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. <i>Cancer Science</i> , 2016, 107, 1465-1470.	3.9	30
34	Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 750-759.	2.6	28
35	Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>International Cancer Conference Journal</i> , 2016, 5, 178-182.	0.5	1
36	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. <i>Breast Cancer</i> , 2016, 23, 329-342.	2.9	49

#	ARTICLE	IF	CITATIONS
37	Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. <i>Breast Cancer</i> , 2016, 23, 73-77.	2.9	13
38	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 90-98.	10.7	84
39	Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 739-750.	2.3	14
40	2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission. <i>Breast Cancer</i> , 2015, 22, 1-4.	2.9	8
41	Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1026-1034.	2.2	37
42	Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 119-127.	2.6	13
43	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. <i>Breast Cancer</i> , 2015, 22, 5-15.	2.9	13
44	Prospective Cohort Study: Whether or Not Patients Benefit from Participation Itself in Randomized-controlled Trials (SELECT BC ECO). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 296-299.	1.3	1
45	Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 703-710.	2.3	25
46	The current status and future perspectives of CSPOR-BC. <i>Breast Cancer</i> , 2013, 20, 287-290.	2.9	0
47	The current status and future perspectives of clinical trial groups in Japan. <i>Breast Cancer</i> , 2013, 20, 285-286.	2.9	1
48	Final Results of a Safety and Efficacy Trial of Preoperative Sequential Chemoradiation Therapy for the Nonsurgical Treatment of Early Breast Cancer: Japan Clinical Oncology Group Study JCOG0306. <i>Oncology</i> , 2013, 85, 336-341.	1.9	13
49	Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1211-1214.	1.3	8
50	Eribulin mesylate in patients with refractory cancers: a Phase I study. <i>Investigational New Drugs</i> , 2012, 30, 1926-1933.	2.6	59
51	Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. <i>Breast Cancer</i> , 2012, 19, 253-258.	2.9	15
52	Safety and Efficacy of a Combination of Docetaxel and Cisplatin in Patients With Unknown Primary Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 32-35.	1.3	10
53	Treatment strategy for HER2-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 335-340.	2.2	23
54	Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East. <i>International Journal of Clinical Oncology</i> , 2010, 15, 578-582.	2.2	10

#	ARTICLE	IF	CITATIONS
55	Elderly Breast Cancer Therapy: A Japanese Experience. Japanese Journal of Clinical Oncology, 2010, 40, 717-721.	1.3	6
56	Randomized Study of Taxane Versus TS-1 in Women with Metastatic or Recurrent Breast Cancer (SELECT BC). Japanese Journal of Clinical Oncology, 2010, 40, 811-814.	1.3	11
57	Targeted Therapy in Breast Cancer: Current Status and Future Directions. Japanese Journal of Clinical Oncology, 2010, 40, 711-716.	1.3	12
58	Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. International Journal of Clinical Oncology, 2009, 14, 431-435.	2.2	4
59	Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Research and Treatment, 2009, 113, 123-128.	2.5	8
60	Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer, 2008, 15, 5-7.	2.9	90
61	An Alternative Medicine, Agaricus blazei, May Have Induced Severe Hepatic Dysfunction in Cancer Patients. Japanese Journal of Clinical Oncology, 2006, 36, 808-810.	1.3	42
62	Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. International Journal of Clinical Oncology, 2003, 8, 23-25.	2.2	9